Navigation Links
Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
Date:7/2/2012

ANAHEIM, Calif., July 2, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ:  QCOR) announced today that executive management will present at the JMP Securities Healthcare Conference in New York on July 13, 2012 at 8:00 a.m. PT / 11:00 a.m. ET.

A live webcast and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm. The replay will be available for approximately 90 days after the event.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of proteinuria in idiopathic types of nephrotic syndrome, the treatment of acute exacerbations of multiple sclerosis in adults, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also currently preparing to
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Access Pharmaceuticals Announces Positive Data From MuGard Phase 4 Clinical Trial In Oral Mucositis At MASCC/ISOO 2012 Symposium
2. Pharmaceuticals: Global Industry Almanac, MarketLine
3. Prodigy Health Supplier Partners with Stason Pharmaceuticals to Help Relieve U.S. Drug Shortages
4. Nouveau Life Pharmaceuticals (NOUV) to Launch Affiliate Sales Program
5. Trading Of Onyx Pharmaceuticals Common Stock Halted
6. Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
7. ADVENTRX Pharmaceuticals To Present At 2012 BIO International Convention Business Forum
8. Michael Cola Joins the Board of Directors of Vanda Pharmaceuticals
9. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
10. Cumberland Pharmaceuticals To Present At The 2012 Wells Fargo Securities Healthcare Conference In Boston
11. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , September 17, 2014 ... GRC 17536, has shown positive data in a Phase ... diabetic neuropathy , Glenmark Pharmaceuticals ... Potential Ankyrin 1 (TRPA1) antagonist, GRC 17536 has shown ... controlled, multi-centre, proof of concept study conducted on 138 ...
(Date:9/17/2014)...  Members of the physician IT team at ... today that the enterprise is working with ... capabilities and provide immediate cluster fail over in ... the Dicom Systems enterprise imaging solutions will be ... more effectively deliver the right images to the ...
(Date:9/17/2014)... 2014 An analysis done by the CVS ... (sofosbuvir), a new and expensive treatment for Hepatitis C ... last several months (May through August 2014) there has ... utilization. This suggests another surge of patients will begin ... similar efficacy and shorter duration are introduced in the ...
Breaking Medicine Technology:Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 2Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 2CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 4
... Event for Congressional Members and Staff Will Focus on Advances ... Research and Treatment of Lung Cancer in ... CTIC; MTAX:), along with the Society for Women,s Health,Research, the ... "Lung Cancer: Being Female Matters to Research," on,Capitol Hill to ...
... in cSSSI, CAMBRIDGE, Mass., Sept. 13 ... Phase 2 trial,investigating the safety and efficacy of ... of Complicated Skin and Skin Structure,Infections (cSSSI), or ... positive infections. This Phase 2 study is ...
Cached Medicine Technology:Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill 2Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill 3Targanta Initiates Phase 2 Oritavancin Infrequent Dosing Study 2Targanta Initiates Phase 2 Oritavancin Infrequent Dosing Study 3
(Date:9/17/2014)... like the ideas of a science fiction writer, ... exciting new approach to imaging local and metastatic ... cancer, scientists at Virginia Commonwealth University Massey Cancer ... Hopkins Medical Institutions have provided proof-of-principle of a ... ability to see tumors that have metastasized to ...
(Date:9/17/2014)... 17, 2014 Catalent Pharma Solutions, ... and development solutions for drugs, biologics and consumer ... an integrated service and technology offer based on ... from the company’s 450,000 sq. ft. Kansas City, ... to integrate optimal formulation, development, analytical expertise, scale ...
(Date:9/17/2014)... 2014 (HealthDay News) -- Positive messages about the health ... the habit, a new study suggests. Although smokers ... "loss-framed" messages about the harmful effects of smoking, researchers ... want benefit more from "gain-framed," or positive, messages about ... concluded that using a mix of both types of ...
(Date:9/17/2014)... New York, New York (PRWEB) September 17, 2014 ... ) filings involving the Conserve line of metal-on-metal ... litigation now underway in U.S. District Court, Northern ... to an updated Case List issued by the ... 15, 2014, at least 397 product liability claims ...
(Date:9/17/2014)... TX (PRWEB) September 17, 2014 Smart ... Editor’s Picks by Progressive Grocer, a leading trade magazine ... was awarded for originality and flavor, among other attributes. ... as an Editor’s Pick in the September print issue ... Grocer website. , The pizza won based on its ...
Breaking Medicine News(10 mins):Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:New OptiPact™ Technology Introduced by Catalent 2Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:Smart Flour Foods Wins 2014 Progressive Grocer Editor’s Pick Award 2
... A new technology called the Cone beam computerized tomography ... to diagnose complicated oral problems.// ,J. Martin ... at the Case Western Reserve University School of Dental ... department of dental health and biological sciences at the ...
... two protein complexes which is found to protect cell ... number of chromosomes leading to cell instability which leads ... research team from Mayo Clinic have found that the ... which maintains the euploidy state in the cell and ...
... The waiting times at Ontario’s hospitals are getting longer, according ... revealed by Elizabeth Witmer, the Conservative health critic.// The waiting ... and September 2005 for cancer surgery, while it rose from ... time increased to 22 days for cardiac surgeries, while in ...
... genetic code is reported to have been cracked by ... faster diagnosis and treatment of the ailment which causes ... Jewish General Hospital’s Dasval. The strain has caused infections ... The search can now commence for the other antibiotic ...
... Institute (SERI) found that increasing the contrast of details ... the visually impaired. // ,The U.S. study provides ... help millions suffering eye diseases. People who may benefit ... degeneration, diabetic retinopathy and other causes of low vision. ...
... National Laboratories, Gerry Yonas was the first to visualize a need ... the development of the BiNational Sustainability Laboratory (BNSL), which extends over ... mainly augment the border security force and deal with terrorism ... ,The monetary inputs for the lab come from USA, ...
Cached Medicine News:Health News:New Computerized Imaging Systems Help In Better Dental Treatment Planning 2Health News:Visually impaired prefer specially enhanced TV 2Health News:Visually impaired prefer specially enhanced TV 3
Cold light source single outlet....
Cold light source triple outlet....
Cold light source single outlet....
... is a state of the ... source with an integrated intensity ... to connect optical fiber light ... itself from all others by ...
Medicine Products: